CMP-001 in Combination With IV PD-1-Blocking Antibody in Subjects With Certain Types of Advanced or Metastatic Cancer
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
CMP-001-009 is a Phase 2 study of intratumoral CMP-001 in combination with an intravenous
PD-1-blocking antibody administered to participants with certain types of advanced or
metatastic cancer.
The primary objective of the study is to determine the Investigator-assessed confirmed
objective response with CMP-001 in combination with a programmed cell death protein
(PD-1)-blocking antibody in subjects with certain types of advanced or metatastic cancer.
The secondary objectives are to:
- To evaluate the safety and tolerability of CMP-001 administered by intratumoral (IT)
injection in combination with a PD-1-blocking antibody in study subjects.
- To evaluate the efficacy of CMP-001 in combination with a PD-1-blocking antibody in
study subjects.
Participants will continue to receive treatment of CMP-001 in combination with a
PD-1-blocking antibody according to the treatment schedule until a reason for treatment
discontinuation is reached.